trending Market Intelligence /marketintelligence/en/news-insights/trending/vOZ9FyBwVXmD3ePw3snGQw2 content esgSubNav
In This List

Nasdaq adds 54 new stocks to Nasdaq Biotechnology Index, junks 15 in reranking

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Nasdaq adds 54 new stocks to Nasdaq Biotechnology Index, junks 15 in reranking

Nasdaq Inc. revealed the annual re-ranking of the Nasdaq Biotechnology Index which will become effective before market opens Dec. 18.

The index added the following new stocks: Arbutus Biopharma Corp., Aclaris Therapeutics Inc., Adaptimmune Therapeutics plc, Achaogen Inc., Akcea Therapeutics Inc., AnaptysBio, Inc., Ascendis Pharma A/S, Athenex Inc., Aurinia Pharmaceuticals Inc., Axovant Sciences Ltd., Bioverativ Inc., Calithera Biosciences, Inc., Cara Therapeutics Inc., Cascadian Therapeutics, Inc., Cellectis SA, Calyxt, Inc., Chimerix, Inc., Concert Pharmaceuticals Inc., Corium International, Inc., Corbus Pharmaceuticals Holdings, Inc., CRISPR Therapeutics AG, Corvus Pharmaceuticals Inc., CytomX Therapeutics Inc., Dova Pharmaceuticals Inc., Endocyte, Inc., Galapagos NV, GlycoMimetics, Inc., G1 Therapeutics Inc., ImmunoGen Inc., Jounce Therapeutics, Inc., Kala Pharmaceuticals Inc., Kura Oncology Inc., Medpace Holdings, Inc., MannKind Corp., Marinus Pharmaceuticals, Inc., Mersana Therapeutics, Inc., MyoKardia Inc., Nabriva Therapeutics plc, Neos Therapeutics Inc., Puma Biotechnology Inc., PetIQ, Inc., uniQure NV, Ra Pharmaceuticals, Inc., Reata Pharmaceuticals Inc., Strongbridge Biopharma plc, Syndax Pharmaceuticals Inc., Sienna Biopharmaceuticals, Inc., Savara Inc., Tocagen Inc., Tetraphase Pharmaceuticals Inc., TherapeuticsMD Inc., Veracyte, Inc., Vital Therapies, Inc. and Voyager Pharmaceutical Corp.

As part of the reranking the stock exchange will remove the following 15 securities from the index: Aquinox Pharmaceuticals, Inc., Aralez Pharmaceuticals Inc., Compugen Ltd., Clearside BioMedical Inc., Impax Laboratories Inc., Merrimack Pharmaceuticals Inc., Cempra, Inc., MediciNova Inc., OncoMed Pharmaceuticals, Inc., Organovo Holdings Inc., Ophthotech Corp., Otonomy, Inc., Trevena Inc., Versartis Inc. and XBiotech Inc.